Sessions
Immunology and Inflammation
10:45 AM - 11:45 AM Thu
Carolyn Britten is currently the Vice President, Global Development, Early Development Oncology. In this role, she oversees Amgen’s portfolio of early development oncology programs, spanning across indications and modalities.
Carolyn joined Amgen in 2019 as an Executive Medical Director in Early Development Oncology, where she managed a number of early development solid tumor programs. She then served as the Global Development Lead and Product Team Lead for Bemarituzumab, guiding the asset through the initiation of two global phase 3 trials, and three phase 1b/2 trials.
She received her MD from the University of Toronto and completed her medical oncology fellowship at the BC Cancer Agency (BCCA) in Vancouver, BC, followed by a research fellowship in Phase 1 Clinical Trials at the Institute for Drug Development in San Antonio, TX. She served for over 11 years as the Phase 1 investigator embedded in Dennis Slamon’s Signal Transduction Laboratory at UCLA, achieving the rank of Associate Professor. She established the Phase 1 program at the NCI-Designated Hollings Cancer Center at the Medical University of South Carolina (MUSC), where she was promoted to Professor and Chief of the Division of Hematology/Oncology. Carolyn also held the position of Associate Director of Clinical Science at Hollings Cancer Center, where she oversaw the Clinical Trials Office, the Data Safety Monitoring Board, and the Scientific Review Committee. Carolyn has served as an examiner for the Royal College of Physicians and Surgeons of Canada, as a member of the ASCO Educational and Scientific Program Committees, and as Program Director for the MUSC Hematology/Oncology Fellowship Program. She has published research in gastrointestinal malignancies, breast cancer, and early drug development across solid tumors.